Evidence map›Paper›PMID 38782983›Full record

ArticleScientific reports2024

Highly variable biological effects of statins on cancer, non-cancer, and stem cells in vitro.

Helena Gbelcová, Silvie Rimpelová, Adriana Jariabková, Patrik Macášek, Petra Priščáková, Tomáš Ruml, Jana Šáchová, Jan Kubovčiak, Michal Kolář, Libor Vítek

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Anti-Tumor Effects of Statins in Pancreatic Ductal Adenocarcinoma Cells.International journal of molecular sciences · 2026
    Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Helena GbelcováInstitute of Medical Biology, Genetics and Clinical Genetics, Faculty of Medicine, Comenius University, Bratislava, 813 72, Slovak Republic. helena.gbelcova@fmed.uniba.sk.
Silvie RimpelováDepartment of Biochemistry and Microbiology, University of Chemistry and Technology, Prague, 166 28, Czech Republic.
Adriana JariabkováInstitute of Medical Biology, Genetics and Clinical Genetics, Faculty of Medicine, Comenius University, Bratislava, 813 72, Slovak Republic.
Patrik MacášekInstitute of Medical Biology, Genetics and Clinical Genetics, Faculty of Medicine, Comenius University, Bratislava, 813 72, Slovak Republic.
Petra PriščákováInstitute of Medical Biology, Genetics and Clinical Genetics, Faculty of Medicine, Comenius University, Bratislava, 813 72, Slovak Republic.
Tomáš RumlDepartment of Biochemistry and Microbiology, University of Chemistry and Technology, Prague, 166 28, Czech Republic.
Jana ŠáchováLaboratory of Genomics and Bioinformatics, Institute of Molecular Genetics, Czech Academy of Sciences, Prague, 142 20, Czech Republic.
Jan KubovčiakLaboratory of Genomics and Bioinformatics, Institute of Molecular Genetics, Czech Academy of Sciences, Prague, 142 20, Czech Republic.
Michal KolářLaboratory of Genomics and Bioinformatics, Institute of Molecular Genetics, Czech Academy of Sciences, Prague, 142 20, Czech Republic.
Libor VítekInstitute of Medical Biochemistry and Laboratory Diagnostics, and 4Th Department of Internal Medicine, 1St Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, 121 08, Czech Republic.

Funding

Czech Ministry of Health MH CZ-DRO-VFN64165Ministry of Education, Research, Development and Youth of the Slovak Republic VEGA-1/0405/22Operational Programme Research, Development, and Education CZ.02.1.01/0.0/0.0/16_019/0000785Slovak Research and Development Agency APVV-15-0217
6 · The paper itself

Abstract

Statins, the drugs used for the treatment of hypercholesterolemia, have come into the spotlight not only as chemoadjuvants, but also as potential stem cell modulators in the context of regenerative therapy. In our study, we compared the in vitro effects of all clinically used statins on the viability of human pancreatic cancer (MiaPaCa-2) cells, non-cancerous human embryonic kidney (HEK 293) cells and adipose-derived mesenchymal stem cells (ADMSC). Additionally, the effect of statins on viability of MiaPaCa-2 and ADMSC cells spheroids was tested. Furthermore, we performed a microarray analysis on ADMSCs treated with individual statins (12 μM) and compared the importance of the effects of statins on gene expression between stem cells and pancreatic cancer cells. Concentrations of statins that significantly affected cancer cells viability (< 40 μM) did not affect stem cells viability after 24 h. Moreover, statins that didn´t affect viability of cancer cells grown in a monolayer, induce the disintegration of cancer cell spheroids. The effect of statins on gene expression was significantly less pronounced in stem cells compared to pancreatic cancer cells. In conclusion, the low efficacy of statins on non-tumor and stem cells at concentrations sufficient for cancer cells growth inhibition, support their applicability in chemoadjuvant tumor therapy.

Indexed as

Cell SurvivalHydroxymethylglutaryl-CoA Reductase InhibitorsMesenchymal Stem CellsPancreatic NeoplasmsCell Line, TumorHEK293 CellsHumansSpheroids, CellularHydroxymethylglutaryl-CoA Reductase Inhibitors3-Hydroxy-3-methylglutaryl coenzyme A inhibitorsCell spheroidsMicroarray analysisPancreatic cancer cellsStatinsStem cells

Identifiers

PMID38782983
PMCPMC11116523

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.